Histotripsy in Biliary Tract Cancer
NCT: NCT07853690 · NOT_YET_RECRUITING
Brief Summary
The purpose of this pilot study is to examine the safety and feasibility of histotripsy in two cohorts of 12 patients each with Biliary Track Cancer (BTC), with a plan to expand to a larger multi-center study if both safety and feasibility are demonstrated. All patients from cohort 1 will be evaluated for objective response rate (ORR), duration of response (DOR), disease control rate (DCR), progression free survival (PFS) and overall survival (OS) of histotripsy in combination with chemoimmunotherapy. Toxicity profile of histotripsy will be characterized for this cohort. For Cohort 2, in addition to the above evaluations, changes in serum bilirubin levels (total and direct) over time, time to biliary decompression or normalization of bilirubin (total and direct), and percent of patients rendered eligible for chemoimmunotherapy with GCD/P will also be assessed.
Frequently Asked Questions
What is Histotripsy in Biliary Tract Cancer?
Histotripsy in Biliary Tract Cancer is a clinical trial registered under NCT07853690. Current status: NOT_YET_RECRUITING.
What is the status of NCT07853690?
The current status of NCT07853690 (Histotripsy in Biliary Tract Cancer) is: NOT_YET_RECRUITING.
When did Histotripsy in Biliary Tract Cancer start?
Histotripsy in Biliary Tract Cancer started on 2026-09.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.